<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01501708</url>
  </required_header>
  <id_info>
    <org_study_id>RJH-2011-71</org_study_id>
    <nct_id>NCT01501708</nct_id>
  </id_info>
  <brief_title>Caspofungin Based Combined Anti-fungal Therapy for Proven or Probable Invasive Fungal Infection</brief_title>
  <official_title>Phase II Study of Caspofungin Based Combined Anti-fungal Therapy for Patients With Proven or Probable Invasive Fungal Infection After Allogeneic Stem Cell Transplantation From HLA-matched Unrelated or HLA-mismatched Related Donors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this prospective phase II observational study, we plan to assess the efficacy and
      tolerability of caspofungin based combined anti-fungal therapy for proven or probable IFI in
      a group of patients received allo-HSCT transplantation with high risk of IFI: HLA matched
      unrelated donor or mismatched donor conditioning with ATG containing regimen or present
      III-IV aGVHD or extensive GVHD undergoing high-dose steroid treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will recieve caspofungin with either voriconazole or amphotericin B as combination
      therapy for fungal infection
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Favorable response rate</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>12 weeks, 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Leukemia</condition>
  <condition>Transplantation, Hematopoietic Stem Cell</condition>
  <arm_group>
    <arm_group_label>Caspofugin based combination therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Caspofugin based combination therapy:
Patients will recieve caspofungin with voriconazole or amphotericin B</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caspofugin based combination therapy</intervention_name>
    <description>Caspofungin: 70 mg on the Ô¨Årst day of therapy, followed by 50 mg q.d.
All patients received azoles as prophylaxis (fluconazole as prophylaxis and itraconazole or voriconazole as secondary prophylaxis), combination with liposomal amphotericin B at a dosage 3mg/kg q.d will be given.
In case of renal function damage, combination with voriconazole 6mg/kg followed by 4 mg/kg b.i.d. will be given.</description>
    <arm_group_label>Caspofugin based combination therapy</arm_group_label>
    <other_name>caspofungin + voriconazole or amphotericin B</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patient undergoing allogeneic hematopoietic stem cell transplantation

          -  age 18-55 years

          -  with inform consent

          -  no contraindication for allogeneic transplantation: active infection, allergy to
             FLu/Bu/CTX, liver and renal function damage

          -  HLA mismatched related (3~5/6) or unrelated donors (at least 8/10)

          -  proven or probable IFI

        Exclusion Criteria:

          -  age less than 18 years or over 56 years

          -  HLA mismatched related donor

          -  liver function/renal function damage (over 2 X upper normal range)

          -  with mental disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ling Wang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rui Jin Hospital, Shanghai JiaoTong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiong HU, M.D.</last_name>
    <phone>86-21-64370045</phone>
    <phone_ext>601818</phone_ext>
    <email>hujiong@medmail.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Blood &amp; Marrow Transplantation Center, RuiJin Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ling Wang, M.D</last_name>
      <phone>86-21-64370045</phone>
      <phone_ext>601818</phone_ext>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2011</study_first_submitted>
  <study_first_submitted_qc>December 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2011</study_first_posted>
  <last_update_submitted>May 9, 2016</last_update_submitted>
  <last_update_submitted_qc>May 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Jiong HU</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>caspofungin</keyword>
  <keyword>IFI</keyword>
  <keyword>allogeneic hematopoietic stem cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Invasive Fungal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Voriconazole</mesh_term>
    <mesh_term>Amphotericin B</mesh_term>
    <mesh_term>Liposomal amphotericin B</mesh_term>
    <mesh_term>Caspofungin</mesh_term>
    <mesh_term>Echinocandins</mesh_term>
    <mesh_term>Antifungal Agents</mesh_term>
    <mesh_term>Miconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

